Associated Vitreoretinal and Uveitis Consultants

03/10/2026

Retinal vein occlusion (RVO) can cause vision loss due to retinal swelling. Recent FDA-approved treatments, including faricimab and higher-dose aflibercept, offer effective ways to reduce swelling and improve sight with fewer injections. Learn more: https://brnw.ch/21x0C1B

Explore latest RVO care: faricimab, Eylea HD, and biosimilars that cut injection burden and protect vision from macular edema.

03/05/2026

At Associated Vitreoretinal and Uveitis Consultants of Indianapolis, we value the trust you place in us when referring your patients. Our team is committed to delivering the highest level of specialized retinal and uveitis care to support both you and your patients every step of the way. Learn more: https://brnw.ch/21x0tPj

03/03/2026

March is National Nutrition Month! Eating a balanced, nutrient-rich diet not only supports overall health but can also help protect your vision. Small, healthy changes to your nutrition can make a big difference for your eyes and well-being.

02/26/2026

A recent study shows that low-dose pilocarpine 0.4% (Qlosi) can safely shrink the pupil in people with presbyopia without affecting the eye’s focusing ability. Researchers say this makes it a promising option for patients looking for non-surgical help with reading and other close-up tasks. Learn more: https://brnw.ch/21x0irB

Optoretinography is an emerging technology used to test light-evoked photoreceptor activity.

02/24/2026

SpliceBio has treated the first patient in a phase 1/2 clinical trial of SB 007, an investigational gene therapy for Stargardt disease. The therapy is designed to restore a missing retinal protein and may help slow or stop vision loss across many genetic forms of the disease. The study will continue to evaluate safety and early effectiveness in patients ages 12 to 65. Learn more: https://brnw.ch/21x0dPZ

The Part B dose-expansion portion is evaluating SB-007 for the treatment of Stargardt disease.

02/19/2026

Dr. Ramana S. Moorthy is a nationally recognized retina and uveitis specialist, educator, and leader in ophthalmology. As President and CEO of AVRUC, he brings decades of clinical, surgical, and academic experience to the care of complex eye diseases. Learn more: https://brnw.ch/21x05U6

02/17/2026

Ocugen has shared encouraging phase 1 trial results for OCU410ST, a gene therapy for Stargardt disease. The treatment slowed lesion growth and showed early signs of improving vision in patients. A larger phase 2/3 trial is now underway, with FDA approval targeted for 2027. Learn more: https://brnw.ch/21x00VG

OCU410ST uses an adeno-associated virus delivery platform for the retinal delivery of the RORA gene.

02/12/2026

Not all eye care is the same. Our blog breaks down the difference between routine vision care and specialty retina care and explains why seeing the right provider matters when it comes to protecting your sight. Read more and learn when it is time to see a retina specialist: https://brnw.ch/21wZTrG

02/11/2026

Ocugen’s new gene therapy, OCU410, is showing promise in early trial results for treating geographic atrophy, a severe form of dry AMD. After 12 months, patients had slower disease progression with no serious side effects. A larger trial is expected in 2026. Learn more: https://brnw.ch/21wZPVp

The trial is evaluating OCU410 (AAV5-RORA) for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration.

02/10/2026

We built it. They loved it. Now we’re back for more! We completed an stunning space in 2024 for AVU Carmel, and next on the glow-up tour is Greenfield! Set to wrap up Summer of 2026! Thank you for trusting us with another build!!! ✨🏗️ Associated Vitreoretinal and Uveitis Consultants BDH

02/05/2026

February is Age-Related Macular Degeneration and Low Vision Awareness Month - a time to shine a light on the leading cause of legal blindness in the US. Age-related macular degeneration affects nearly 10 million people and can impact central vision, making daily tasks like reading and driving difficult. Early detection and new treatments can make a difference. Learn more: https://brnw.ch/21wZGvs

02/03/2026

In this video, Dr. Ramana Moorthy shares how our physicians lead clinical trial programs and work to bring new treatments to patients. Your participation plays a vital role in advancing the future of retinal care. Watch to learn how research starts with you.